Related Experiment Video
Updated: Jun 26, 2026

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
Published on: September 22, 2023
P2 Receptors as Therapeutic Targets in Allergic Rhinitis: Insights From the Use of Natural Products and Preclinical
Thalita Calvet Pereira1,2, Leandro Rocha2,3, Robson Xavier Faria1
1Laboratory of Environmental Health Assessment and Promotion, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil, fiocruz.br.
Abstract:
Allergic rhinitis (AR) is a chronic inflammatory disorder of the upper airways that is mediated by immunoglobulin E (IgE) and triggered by environmental allergens. Current pharmacological therapies, including antihistamines, corticosteroids, and immunotherapy, offer symptomatic relief but are limited by their incomplete disease-modulating effects and potential adverse side effects. Purinergic P2 receptors (P2Rs; P2X and P2Y subtypes) have emerged as key modulators of allergic inflammation and regulate mast cell degranulation, T helper 2 (Th2) cytokine release, eosinophil recruitment, and NLRP3 inflammasome activation. Natural products, including polyphenols, flavonoids, terpenoids, and alkaloids, demonstrate multitarget anti-inflammatory effects and have the potential to modulate P2R signaling. However, direct evidence of their activity on P2Rs in AR remains limited. This review critically summarizes the immunopathology of AR, highlights the functional relevance of P2Rs, and discusses emerging natural product-based strategies, emphasizing mechanistic insights and translational potential for the development of novel therapeutics.
Related Concept Videos
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Allergic Reactions
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
